Development and Diligence Sample Clauses

The DEVELOPMENT AND DILIGENCE clause sets out the obligations of a party, typically a licensee or developer, to actively pursue the development and commercialization of a product or technology. It often requires the party to meet specific milestones, adhere to timelines, or demonstrate reasonable efforts in progressing the project. This clause ensures that the licensed technology or project is not left idle and that both parties benefit from timely and effective development, thereby reducing the risk of stagnation and aligning interests toward successful outcomes.
Development and Diligence. 5.1 Regulatory. LIRUM will be solely responsible for all regulatory matters related to the Exploitation of the Licensed Product in the Territory, including without limitation taking full responsibility for preparing and filing the relevant applications with the Regulatory Authorities for pre-clinical and clinical studies and for Regulatory Approvals. LIRUM shall have the right to file in its own name, and to own all regulatory filings and new Regulatory Approvals for the Compounds and Licensed Products in the Field in the Territory.
View SourceView Similar (2)
Development and Diligence. 6.1 In connection with the development and commercialization of Licensed Product(s), OXFORD shall have access to information regarding SSI’s manufacture of the Diagnostic Antigens as well as the quality systems for said manufacture, exclusively for OXFORD’s use in its regulatory filings on Licensed Product(s). SSI shall have access to Diagnostic Antigens data produced by or on behalf of OXFORD and to all of OXFORD’s relevant correspondence with all regulatory agencies involving Diagnostic Antigens, provided, however, that SSI shall not use any such information commercially. Where reasonably advisable, OXFORD shall use reasonable efforts to include SSI in meetings and videoconferences with regulatory agencies involving Diagnostic Antigens. 6.2 OXFORD shall bear all costs associated with all clinical trials conducted in connection with Licensed Product(s) and undertake at its expense all regulatory activities related to Licensed Product(s). Except where prohibited by local laws, OXFORD shall file and shall be the holder of Regulatory Approval(s) for Licensed Product(s), all at its expense. OXFORD undertakes to use all reasonable efforts to supply those Licensed Products that are designated for Research Use Only solely to Third Parties who shall use the Licensed Products in accordance with all relevant national and international ethical, quality, safety and other applicable guidelines, including but not limited to use in any clinical trial or study. Oxford undertakes that in any such clinical trial, it will not itself give any clinical diagnosis of a patient. OXFORD further undertakes that where it is the Sponsor for any clinical trial or study involving the Licensed Product (as defined by the rules and/or guidelines applicable in the country hosting said trial or study, including any applicable GCP guidelines), it shall carry out each such trial or study in accordance with all relevant national and international ethical, quality, safety and other applicable guidelines, including but not limited to any applicable GCP guidelines. 6.3 OXFORD agrees to exert its best endeavors in pursuing the timely development and commercialization of Licensed Product(s) in [***], and, to the extent that there is a reasonable potential commercial opportunity, other markets worldwide, including, but not limited to, conducting all appropriate clinical studies, obtaining the appropriate Regulatory Approval for Licensed Product(s) and expanding markets and customer bases for Licens...
View SourceView Similar (2)
Development and Diligence. Any and all requirements imposed on Alseres by the License Agreement to develop and/or commercialize Products (as defined in the License Agreement), maintain insurance, keep the Master Cell Bank intact and other similar obligations will be eliminated including but not limited to any and all rights of BA to terminate the licensed based on Diligence milestones (as defined in the License Agreement).
View Source
Development and Diligence. 5.1. The Company shall use reasonable commercial efforts to develop the Product(s) in accordance with the Development Plan which describes a proposed preclinical and clinical development plan extending [***] from the Effective Date showing the activities planned to advance the Licensed Products, as may be amended by the Company from time to time, subject to the provisions of section 5.2 below, to introduce the Product to as extensive a market in major countries as is reasonably possible and as soon as reasonably practical, to market, sell, support, service, license, sub-license and otherwise create income and value for the Company, all consistent with sound and reasonable business practices and judgment in the pharmaceutical industry in general, and the Company’s business discretion as may be modified by Company from time to time. 5.2. The Company shall be entitled, from time to time, to make such adjustments to the Development Plan as the Company believes, in its good faith judgment, are needed in order to improve the Company’s ability to commercialize the Products(s). The Company shall notify Licensor promptly regarding material changes to the Development Plan, which shall detail the reasons thereof.
View Source
Development and Diligence 
View SourceView Similar (5)

Related to Development and Diligence

  • Development Diligence Pfizer will use its Commercially Reasonable Efforts to Develop and seek Regulatory Approval for one Product in the Field in [***]. Pfizer will have no other diligence obligations with respect to the Development or Regulatory Approval of Products under this Agreement.

  • Development Activities The Development activities referred to in item “b” of paragraph 3.1 include: studies and projects of implementation of the Production facilities; drilling and completion of the Producing and injection ▇▇▇▇▇; and installation of equipment and vessels for extraction, collection, Treatment, storage, and transfer of Oil and Gas. The installation referred to in item “c” includes, but is not limited to, offshore platforms, pipelines, Oil and Gas Treatment plants, equipment and facilities for measurement of the inspected Production, wellhead equipment, production pipes, flow lines, tanks, and other facilities exclusively intended for extraction, as well as oil and gas pipelines for Production Outflow and their respective compressor and pumping stations.

  • Development and Commercialization Subject to Sections 4.6 and 4.7, Fibrocell shall be solely responsible for the development and Commercialization of Fibrocell Products and Improved Products. Fibrocell shall be responsible for all costs incurred in connection with the Fibroblast Program except that Intrexon shall be responsible for the following: (a) costs of establishing manufacturing capabilities and facilities in connection with Intrexon’s manufacturing obligation under Section 4.6 (provided, however, that Intrexon may include an allocable portion of such costs, through depreciation and amortization, when calculating the Fully Loaded Cost of manufacturing a Fibrocell Product, to the extent such allocation, depreciation, and amortization is permitted by US GAAP, it being recognized that the majority of non-facilities scale-up costs cannot be capitalized and amortized under US GAAP); (b) costs of basic research with respect to the Intrexon Channel Technology and Intrexon Materials (i.e., platform improvements) but, for clarity, excluding research described in Section 4.7 or research requested by the JSC for the development of a Fibrocell Product or an Improved Product (which research costs shall be reimbursed by Fibrocell); (c) [*****]; and (d) costs of filing, prosecution and maintenance of Intrexon Patents. The costs encompassed within subsection (a) above shall include the scale-up of Intrexon Materials and related active pharmaceutical ingredients for clinical trials and Commercialization of Fibrocell Products undertaken pursuant to Section 4.6, which shall be at Intrexon’s cost whether it elects to conduct such efforts internally or through Third Party contractors retained by either Intrexon or Fibrocell (with Intrexon’s consent).

  • Commercial Diligence Pfizer will use Commercially Reasonable Efforts to Commercialize a given Agreement Product in each Major Market Country in the Field in the Territory where Pfizer or its Affiliates have received Regulatory Approval for such Agreement Product. Pfizer will have no other diligence obligations with respect to the Commercialization of Agreement Products under this Agreement.

  • Development Work The Support Standards do not include development work either (i) on software not licensed from CentralSquare or (ii) development work for enhancements or features that are outside the documented functionality of the Solutions, except such work as may be specifically purchased and outlined in Exhibit 1. CentralSquare retains all Intellectual Property Rights in development work performed and Customer may request consulting and development work from CentralSquare as a separate billable service.